Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2020-04-17 Capital/Financing Update
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 16, 2020, by Moleculin Biotech, Inc. It includes disclosures about an investor webinar and an investor presentation (Exhibit 99.1). The main content describes an update on the company's at-the-market offering (ATM) sales agreement and recent share issuances, including proceeds and fees paid. The document does not contain detailed financial statements or comprehensive financial analysis but rather provides an update on financing activities and includes an investor presentation as an exhibit. The presence of detailed information about share issuance and proceeds aligns with a Capital/Financing Update. The investor presentation is referenced as an exhibit but the main filing is focused on financing updates. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (5405 characters) is sufficient to contain substantive information, not just a brief announcement, supporting this classification.
2020-04-17 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 15, 2020. It announces that Dr. Dominique Schols has joined the company's development team as a consultant. The document includes a press release as an exhibit. There are no financial statements, detailed financial data, or comprehensive reports included. The document is a regulatory announcement of a corporate event rather than a financial report or detailed management discussion. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Management Reports.
2020-04-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 14, 2020. It announces an upcoming web-based conference call hosted by the CEO to discuss a recent scientific discovery related to the company's compound. The document includes a press release as an exhibit. There are no financial statements or detailed financial data included, and the document is relatively short (3464 characters). The content is primarily an announcement of an event (conference call) and a press release, not a full earnings release or detailed financial report. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-04-14 English
Regulatory Filings 2020
Regulatory Filings
2020-04-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 8, 2020, by Moleculin Biotech, Inc. It reports an event under Item 8.01 "Other Events," specifically the issuance of a press release about independent research findings related to COVID-19. The document includes a press release as an exhibit but does not contain financial statements or detailed financial data. The length is 3346 characters, which is relatively short and consistent with a current report announcing a specific event rather than a full financial report. There is no indication of earnings data, management discussion, or other report types. Therefore, this is a Current Report on Form 8-K, which falls under Regulatory Filings (RNS) as a general regulatory announcement and does not fit other more specific categories.
2020-04-08 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a formal correspondence related to a securities registration process, not a financial report or detailed filing. The document is short (959 characters) and does not contain financial data or report content. It is an official regulatory communication related to capital raising but does not provide financing details itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and correspondence that do not fit other specific categories.
2020-04-07 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.